OmniRayn is the applied surface of the MightyCloud cognitive engine. Foundation-model BGC discovery, genome-guided supplements, and cryptographic-implementation analytics — built on a single architecture, validated under orthogonal null controls.
Cross-kingdom validation across seven medicinal Basidiomycete and Ascomycete genomes. Every candidate tested against compositional and intergenic null distributions before reporting. Architectural-class evidence only — no pharmacological claims; no compound has been isolated, characterised, or tested.
Cryptographic-implementation analytics for custody, exchanges, OTC, and analytics firms. Scans on-chain address universes for weak-RNG, nonce-reuse, and known-bad-library wallets — finds the deployments that leak before attackers do.
Foundation-model biosynthetic-gene-cluster discovery with orthogonal null-control verification. Validated on seven medicinal-mushroom genomes; one robust Type I polyketide candidate in Lentinula edodes survived every null applied.
First product designed via the OmniRayn genome engine: a genome-guided functional supplement. Lentinula edodes XR1 + AHCC + Astragalus + Ceylon Cinnamon. DSHEA-compliant 90-day market-entry track. Patent-filed name: Shiitake-Bridge.
Every OmniRayn product runs on the same MightyRayn cognitive engine. Per-domain translators and reference libraries vary; the inference core is fixed. Architecture advances compound across the line.
Foundation-model BGC discovery. Cross-kingdom validation. One robust statin-class hit in shiitake.
Cryptographic-implementation analytics. Weak-RNG, nonce-reuse, known-bad-library detection. Concierge v1.
Genome-guided supplement. First product designed via the engine. DSHEA-compliant track. Patent-filed: Shiitake-Bridge.
Self-serve genome-design workbench. Customers build their own plant-genome products. Cloud + VM appliance.
Dual-signal consensus engine. 18 Pfam HMM profiles × 12 BGC classes. Cross-genome validation complete.
AHCC / Cordyceps / medicinal-fungi BGC pipeline. Validation library. Productized post-FirstRayn.
Most BGC ranking pipelines distinguish only between “real DNA” and shuffled DNA. We add a second layer that distinguishes BGCs from random non-BGC regions of the same organism's own genome. Most candidates fail the second layer. The ones that survive are the ones we report.
A compositional null (dinucleotide-preserving shuffle) tests whether a candidate looks like real genomic sequence at all. An intergenic null (in-distribution windows from the same organism) tests whether the embedding distance actually separates BGCs from random non-BGC genome of the same organism. Most pipelines skip the second; we run both, every candidate, every time.
Each candidate locus passes through a 7-billion-parameter nucleotide foundation model and is embedded into a high-dimensional pattern space. We do not truncate or PCA-reduce. Why: biosynthetic signal is carried in part by the tail of the hidden state — practitioner truncation to 256 or 512 dims loses information that materially changes the candidate ranking.
Architectural features align with the statin family. We make no claim about pharmacological behavior or compound chemistry — no compound has been isolated, characterised, or tested. The result is a genomic architecture finding, not a drug claim. Full per-cluster detail is in the manuscript currently in submission.
Reviewer copy with deeper detail available under NDA — research@mightycloud.org
Modern cryptographic primitives are sound when implemented correctly. The software wrapping them is not always sound. When a wallet library ships with weak RNG, or a signer reuses a nonce, every key generated under those conditions is recoverable from public chain data — forever. Sentinel finds the deployments where implementation leaked.
You send an address list, an xpub, or a scoped wallet universe through the intake form. NDA-gated. Input is hashed and logged for audit; we do not retain your address lists beyond the dispute window.
Our engine runs your universe against Sentinel's detection suite: weak-RNG clustering, nonce-reuse, correlated-nonce patterns, known-bad-library fingerprints. Scans are deterministic — same input always produces same output.
Within 3–5 business days you receive a PDF report, a signed JSON findings file, and a 30-minute consult with an OmniRayn engineer to walk through findings and remediation options.
Without being told where to look. Same engine customers receive in production. Detailed validation methodology is covered under NDA; operator can speak to it directly on a pilot call.
Third-party context: Chainalysis Crypto Crime Report 2026; Unciphered's Randstorm public disclosure (Nov 2023); the Breaking Bitcoin / Real World Crypto talks on ECDSA nonce reuse in the wild.
Sentinel is a passive analysis service. We do not execute trades, transfer funds, or access customer signing infrastructure. Findings are provided as-is; customers make their own remediation decisions. Well-implemented ECDSA on secp256k1 remains cryptographically secure — we identify implementation leakage, not breakage of sound cryptography.
FirstRayn is the first finished product designed via the OmniRayn genome engine. Patent-filed name: “Shiitake-Bridge.” A four-component formulation built around a Lentinula edodes XR1 BGC architecture identified by Discovery, paired with three established functional ingredients to bridge the in-vivo absorption pathway. DSHEA-compliant 90-day market-entry track.
Shiitake mushroom · chr. 5 BGC architecture · 50 Mb genome scan
Established functional ingredients chosen for absorption / pathway support.
Across the 50 Mb genome scan. Architectural class only; no compound isolated.
Functional supplement classification. No medical claims.
Patent bridging note. Commercial brand is FirstRayn. The patent is filed under Shiitake-Bridge in App #64/043,364 (Apr 18, 2026). All commercial assets carry the bridging footnote: “FirstRayn (fka Shiitake-Bridge, as filed in App #64/043,364).” The patent record stays at the filed name; public copy uses FirstRayn.
OmniRayn products are concierge-delivered today. Every engagement runs under NDA. Self-serve API access ships post-CIP for Sentinel; BuildRayn lands as a self-serve workbench in 8–12 weeks.
First three reference customers. Concierge delivery: customer emails request, we run scan, we email PDF + signed JSON. 30% reference-customer credit toward future engagements.
Cross-species therapeutic-bridge licensing for biotech, nutraceutical, and pharma partners. Per-engagement scope. License + revenue share + co-development optionality.
For qualified academic reviewers, foundation grant evaluators, and accredited investors. Get the deeper-detail paper variant including refinement procedure, exact parameter regimes, full benchmark numerics, and per-domain ablations.
The MightyRayn cross-domain validation paper covers ten signal domains under a single fixed inference core. OmniRayn Discovery is described at architectural-class level; full per-cluster detail and methodology internals are available to qualified reviewers under NDA.
Cross-domain pattern recognition has been bottlenecked by domain-specific architectures. We introduce a unified cognitive architecture that performs canonical-pattern classification across heterogeneous signal domains via a single, fixed inference core. The same core powers OmniRayn Discovery (BGCs), OmniRayn Sentinel (crypto-implementation), and the seven other domains in the MightyRayn DETECT product.
Aggregated, class-level validation across ten domains: financial time series, genomic variants, medical waveforms, encrypted traffic, blockchain transactions, neural-network weights, text retrieval, seismic, atmospheric, and behavioural signals. Patent pending.
Authors: MightyCloud Collective Research
Status: Public release (v2). Reviewer copy with full methodological detail available under NDA — research@mightycloud.org.
All OmniRayn technology is protected by one or more pending United States and international patent applications, filed by MightyCloud Collective during April 2026. PCT international filings on track for the 12-month conversion window.
Trademarks: MIGHTYRAYN (Class 9 + 42), RAYNCLOUD, MIGHTYCLOUD. OmniRayn, FirstRayn, and Sentinel are trademarks of MightyCloud Collective. Application status and patent numbers are not disclosed in marketing material; available to qualified reviewers under NDA.
All conversations run under NDA. We respond within one business day.
First-touch inbox. Discovery licensing inquiries. FirstRayn licensing. General questions about the product line.
Pilot requests, scoping calls, NDA exchange, scan delivery, remediation walkthroughs. On-call coverage during pilot wave 1.
Reviewer-copy requests for academic reviewers, foundation grant evaluators, and accredited investors. Mutual NDA template available.
Confidentiality is mutual. Customer data — address universes for Sentinel, genomic material for Discovery — is handled under written NDA. Pre-publication assemblies and proprietary strains are never included in training datasets or external reference releases.